270 related articles for article (PubMed ID: 36430440)
1. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
Ruff SM; Shannon AH; Pawlik TM
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
[TBL] [Abstract][Full Text] [Related]
2. Advances in immunotherapy for biliary tract cancers.
Zhao Y; Yang M; Feng J; Wang X; Liu Y
Chin Med J (Engl); 2024 Mar; 137(5):524-532. PubMed ID: 37646139
[TBL] [Abstract][Full Text] [Related]
3. How I treat biliary tract cancer.
Lamarca A; Edeline J; Goyal L
ESMO Open; 2022 Feb; 7(1):100378. PubMed ID: 35032765
[TBL] [Abstract][Full Text] [Related]
4. Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake.
Rakké YS; Buschow SI; IJzermans JNM; Sprengers D
Front Immunol; 2024; 15():1357333. PubMed ID: 38440738
[TBL] [Abstract][Full Text] [Related]
5. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.
Donne R; Lujambio A
Hepatology; 2023 May; 77(5):1773-1796. PubMed ID: 35989535
[TBL] [Abstract][Full Text] [Related]
6. Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).
Roth GS; Verlingue L; Sarabi M; Blanc JF; Boleslawski E; Boudjema K; Bretagne-Bignon AL; Camus-Duboc M; Coriat R; Créhange G; De Baere T; de la Fouchardière C; Dromain C; Edeline J; Gelli M; Guiu B; Horn S; Laurent-Croise V; Lepage C; Lièvre A; Lopez A; Manfredi S; Meilleroux J; Neuzillet C; Paradis V; Prat F; Ronot M; Rosmorduc O; Cunha AS; Soubrane O; Turpin A; Louvet C; Bouché O; Malka D
Eur J Cancer; 2024 May; 202():114000. PubMed ID: 38493667
[TBL] [Abstract][Full Text] [Related]
7. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs).
Han S; Lee SY; Wang WW; Tan YB; Sim RHZ; Cheong R; Tan C; Hopkins R; Connolly J; Shuen WH; Toh HC
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33212880
[TBL] [Abstract][Full Text] [Related]
8. Temporal Trends of Stages and Survival of Biliary Tract Cancers in the United States and Associations with Demographic Factors.
Wen W; Mumma M; Zheng W
Cancer Epidemiol Biomarkers Prev; 2023 Nov; 32(11):1660-1667. PubMed ID: 37606709
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy in biliary tract cancers-current limitations and potentials in the future.
Sahu S; Sun W
J Gastrointest Oncol; 2017 Apr; 8(2):324-336. PubMed ID: 28480071
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy: A Sharp Curve Turn at the Corner of Targeted Therapy in the Treatment of Biliary Tract Cancers.
Al Mahmasani L; Harding JJ; Abou-Alfa G
Hematol Oncol Clin North Am; 2024 Jun; 38(3):643-657. PubMed ID: 38423933
[TBL] [Abstract][Full Text] [Related]
11. Current biologics for treatment of biliary tract cancers.
Zhao DY; Lim KH
J Gastrointest Oncol; 2017 Jun; 8(3):430-440. PubMed ID: 28736630
[TBL] [Abstract][Full Text] [Related]
12. Unresectable biliary tract cancer: Current and future systemic therapy.
Zhang D; Dorman K; Westphalen CB; Haas M; Ormanns S; Neumann J; Seidensticker M; Ricke J; De Toni EN; Klauschen F; Algül H; Reisländer T; Boeck S; Heinemann V
Eur J Cancer; 2024 May; 203():114046. PubMed ID: 38626513
[TBL] [Abstract][Full Text] [Related]
13. Top Hepatobiliary Articles from 2022 to Inform Your Cancer Practice.
Brown ZJ; Pawlik TM
Ann Surg Oncol; 2024 Jan; 31(1):75-80. PubMed ID: 37843669
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges.
Zheng S; Chan SW; Liu F; Liu J; Chow PKH; Toh HC; Hong W
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672664
[TBL] [Abstract][Full Text] [Related]
15. Overcoming resistance to immune checkpoint blockade in liver cancer - stronger together?
Werner W; Kuzminskaya M; Lurje I; Tacke F; Hammerich L
Semin Liver Dis; 2024 May; ():. PubMed ID: 38806159
[TBL] [Abstract][Full Text] [Related]
16. Perioperative and palliative systemic treatments for biliary tract cancer.
Taghizadeh H; Dong Y; Gruenberger T; Prager GW
Ther Adv Med Oncol; 2024; 16():17588359241230756. PubMed ID: 38559612
[TBL] [Abstract][Full Text] [Related]
17. Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives.
Toledo B; Deiana C; Scianò F; Brandi G; Marchal JA; Perán M; Giovannetti E
Expert Rev Clin Pharmacol; 2024 Apr; 17(4):323-347. PubMed ID: 38413373
[TBL] [Abstract][Full Text] [Related]
18. Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers.
Demir T; Moloney C; Mahalingam D
Crit Rev Oncol Hematol; 2024 May; 199():104388. PubMed ID: 38754771
[TBL] [Abstract][Full Text] [Related]
19. Advanced gallbladder cancer with high tumor mutation burden: a case report and literature review.
Wang J; Liu J; Yan C; Wang K; Li Q; Yu J
AME Case Rep; 2024; 8():53. PubMed ID: 38711896
[TBL] [Abstract][Full Text] [Related]
20. Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy.
Sarantis P; Tzanetatou ED; Ioakeimidou E; Vallilas C; Androutsakos T; Damaskos C; Garmpis N; Garmpi A; Papavassiliou AG; Karamouzis MV
Am J Transl Res; 2021; 13(12):13246-13260. PubMed ID: 35035673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
